LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

34.56 -0.6

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

34.42

Max

35.19

Schlüsselkennzahlen
By Trading Economics
Einkommen	-22M -102M
Angestellte	258
EBITDA	-30M -109M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+45.25% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	666M 6.3B
Vorheriger Eröffnungskurs	35.16
Vorheriger Schlusskurs	34.56

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Mai 2026, 23:55 UTC

Ergebnisse

Review & Preview: Still Going Strong -- Barrons.com

8. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Mai 2026, 20:49 UTC

Ergebnisse

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8. Mai 2026, 20:25 UTC

Ergebnisse

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8. Mai 2026, 19:43 UTC

Ergebnisse

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8. Mai 2026, 19:43 UTC

Ergebnisse

Cencosud 1Q Net $115M

8. Mai 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8. Mai 2026, 19:18 UTC

Ergebnisse

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8. Mai 2026, 19:16 UTC

Ergebnisse

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8. Mai 2026, 19:08 UTC

Ergebnisse

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8. Mai 2026, 19:05 UTC

Ergebnisse

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8. Mai 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8. Mai 2026, 18:51 UTC

Ergebnisse

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8. Mai 2026, 18:49 UTC

Ergebnisse

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8. Mai 2026, 18:41 UTC

Ergebnisse

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8. Mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8. Mai 2026, 17:14 UTC

Ergebnisse

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8. Mai 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8. Mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. Mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Mai 2026, 15:39 UTC

Market Talk

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8. Mai 2026, 15:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Mai 2026, 15:39 UTC

Market Talk

Canada's Job Market Sees Worst Start in Years -- Market Talk

8. Mai 2026, 15:36 UTC

Market Talk

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8. Mai 2026, 15:20 UTC

Market Talk

'Altcoin Season' Indicator on the Rise -- Market Talk

8. Mai 2026, 15:20 UTC

Market Talk

Ergebnisse

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8. Mai 2026, 15:05 UTC

Market Talk

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8. Mai 2026, 14:42 UTC

Market Talk

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8. Mai 2026, 14:39 UTC

Market Talk

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

45.25% Vorteil

12-Monats-Prognose

Durchschnitt 52.1 USD 45.25%

Hoch 64 USD

Tief 35 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.